Unsubscribe

Top

References

Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6): 707-715.
Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141-149.
Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America patient registry sample. J Clin Neurol. 2019;15(3):376-385.
Anil R, Kumar A, Alaparthi S, et al. Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry–The EXPLORE-MG registry. J Neurol Sci. 2020;414.
Nowak RJ. Myasthenia gravis: challenges and burdens of disease. Neurology Reviews. March 2018. https://www.neurologyreviewsdigital.com/ neurologyreviews/nord_supplement_0318/MobilePagedArticle.action?articleId=1361082#articleId1361082
The CIE. The cost to patients and the community of Myasthenia Gravis. Centre for International Economics; November 2013. Accessed August 5, 2020. http://www.thecie.com.au/wp-content/uploads/2014/06/Final-report_Economic-Impact-of-Myasthenia-Gravis-08112013.pdf
Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.
Kaminski HJ, Kusher LL. Myasthenia Gravis and Related Disorders. 3rd ed. Humana Press. 2018.
Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.
Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22(7):1164-1169.
Howard JF Jr. Clinical Overview of MG. Accessed April 20, 2022. https://myasthenia.org/Professionals/Clinical-Overview-of-MG/
Ludwig RJ, Vanhoorelbeke K, Leypoldt F, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603.
Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113-128.
Burden SJ, Yumoto N, Zhang W. The role os MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol. 2013;5(5):a009167.
Lindstrom J, Seybold M, Lennnon V, et al. Antibody to acetylcholine receptor in myasthenia gravis. Neurology. 1976;26:1054-1059.
Vincent A, Newson-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985;48:1246-1252.
Nagane Y, Muri H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7(2);e013278.
Twork S, Wiesmeth S, Flewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.
Simpson JA, Thomaides T. Treatment of myasthenia gravis: an audit. Q J Med.1987;64(244):693-704.

UNSUBSCRIBE

For US Healthcare Professionals Only

www.gMGNeverRests.com says